Ouroboros Family Founders Fund I, LP announced it will lead a $60 million Series A financing round in Cytotheryx, Inc., a preclinical cell therapy company focused on developing innovative treatments for liver disease. The announcement was made at the 2026 Biotech Showcase in San Francisco. The investment is expected to accelerate multiple research programs toward clinical development, expand manufacturing capabilities, and support regulatory planning.
Health Technology Insights: Solventum Wins Diamond HIRC Badge for Top Supply Chain Strength
Cytotheryx also revealed debt financing to grow its real estate footprint and build additional good manufacturing practice capacity. The collaboration reflects the alignment of Ouroboros’ Community Wellness investment strategy with Cytotheryx’s mission to address urgent unmet needs in liver disease. Ouroboros cited Cytotheryx’s proprietary bio-incubator platform, its ability to produce scalable functional human hepatocytes, and the management team’s proven execution across multiple therapeutic programs as key factors in its decision.
Richard Tannenbaum, Managing Partner at Ouroboros Family Founders Fund, said, “Cytotheryx represents a high-impact investment in healthcare with strong commercial potential. The company has created a differentiated technology platform that targets a critical clinical need where existing solutions are limited.” This funding demonstrates continued investor confidence in next-generation cell and gene therapy platforms despite a challenging biotech environment.
Health Technology Insights: OrthAlign Expands Lantern Hip Platform for Posterior THA
Cytotheryx’s portfolio includes a bio-incubator platform for producing liver cells at scale, a bioartificial liver support system for acute liver failure, and universal liver cells for transplantation. Subject to closing, Ouroboros will take a board observer position and provide strategic guidance throughout Cytotheryx’s development journey. Dr. John R. Swart, CEO of Cytotheryx, said, “We are excited to partner with Ouroboros as we advance our cell therapy platform toward clinical trials. This financing provides the resources to scale our manufacturing operations and progress multiple programs through critical milestones in development.”
Health Technology Insights: Ferronova Raises $6 Million to Boost Image-Guided Cancer Surgery
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
